InhibRx Biosciences, Inc
Clinical trials sponsored by InhibRx Biosciences, Inc, explained in plain language.
Clinical-stage biotech developing antibody therapeutics for cancer.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
-
New antibody drug takes aim at Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage trial tests a new drug called INBRX-109 in people with advanced solid tumors, including Ewing sarcoma and colorectal cancer. The drug is designed to attach to a protein on cancer cells and trigger their death. The main goals are to check safety and see if the dru…
Phase 1 • Sponsor: Inhibrx Biosciences, Inc • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
New antibody combo aims to supercharge immune system against Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase trial is testing an experimental drug called INBRX-106, alone or combined with the immunotherapy Keytruda, in people with advanced solid tumors (including lung, head and neck, melanoma, and others) that have stopped responding to standard treatments. The main goa…
Phase 1/2 • Sponsor: Inhibrx Biosciences, Inc • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC